Pharmacodynamic Effects and Predictive Biomarkers of JAK/STAT Inhibition With Ruxolitinib in Operable Head and Neck Cancer: a Window Trial
Phase of Trial: Phase II
Latest Information Update: 24 Jan 2019
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Carcinoma; Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 16 Jan 2019 Status changed from not yet recruiting to recruiting.
- 31 Aug 2018 Biomarkers information updated
- 23 Apr 2018 Planned initiation date changed from 31 Jan 2018 to 1 Nov 2018.